- £46.60m
- £43.10m
- £6.00m
U.S. FDA clearance for SpydrBlade™ Flex
Director/PDMR Shareholding
Posting of AR&R and Notice of AGM
Holding(s) in Company
Holding(s) in Company
Directorate changes
Brief: Creo Medical Group Announces FY24 Results In Line With Expectations
Final Results
Notice of Results
Holding(s) in Company
Grant of Options
Brief: Creo Medical Group Expects Revenues Of £30.4 Million For 2024
FY24 Trading Update
First Welsh adopter of Speedboat® technology
Award of Shares under Share Incentive Plan
First robotic-guided lung ablation cases commence
Director/PDMR Shareholding
Director/PDMR Shareholding
Europe Research Roundup: Assa Abloy, Kering, L'Oréal